As filed with the Securities and Exchange Commission on January 22, 2021
Registration No. 333-232315
Registration No. 333-237412
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO.
333-232315
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM
S-8 REGISTRATION STATEMENT NO. 333-237412
PREVAIL
THERAPEUTICS INC.
(Exact name of issuer as specified in its charter)
|
|
|
Delaware
|
|
82-2129632
|
(State of incorporation)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
430 East 29th Street, Suite 1520
New York, NY
(917) 336-9310
|
|
10016
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
2017 EQUITY INCENTIVE PLAN
2019 EQUITY INCENTIVE PLAN
2019 EMPLOYEE STOCK PURCHASE PLAN
(Full title of plan)
Kenneth L. Custer
President
Prevail
Therapeutics Inc.
430 East 29th Street, Suite 1520
New York, NY 10016
(917)
336-9310
(Name, address and telephone number of agent for service)
Copy to:
Raymond O. Gietz, Esq.
Matthew J. Gilroy, Esq.
Weil, Gotshal & Manges LLP
767 Fifth Avenue
New
York, New York 10153
(212) 310-8000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated
filer a smaller reporting company or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company and emerging growth company in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer
|
|
☐
|
|
Accelerated filer
|
|
☐
|
|
|
|
|
Non-accelerated filer
|
|
☒
|
|
Smaller reporting company
|
|
☒
|
|
|
|
|
|
|
|
|
Emerging growth company
|
|
☒
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐